Zylox-Tonbridge Medical Technology Co., Ltd. to announced on September 27, 2021 that, neurovascular embolization coils, independently developed in-house by the Company, has been granted the marketing approval by the National Medical Products Administration of the People's Republic of China (the "NMPA") for the treatment of Intracranial Hemorrhagic Stroke. Intracranial aneurysm embolization coil is a Class III and implantable medical device. neurovascular embolization coils are a set of flexible coils used in the endovascular coiling procedure, which is a minimally invasive technique using a catheter to reach the aneurysm in the brain, displace the coils to block the blood flowing into the aneurysm, thus reducing the risk of aneurysm rupture. have completed a multi-center, single-blind non-inferiority trial in China to evaluate the efficacy and safety of neurovascular embolization coils. The procedures for the trial were completed in 11 centers and enrolled a total of 256 subjects, with Changhai Hospital, a Class III Grade A hospital specializing in neurovascular diseases, as the leading principal investigative institution. In conclusion, the comprehensive trial results demonstrated noninferiority as compared to a market-leading commercialized neurovascular embolization coil developed by an international medical device company (the comparable product). Compared to other major coils on the market, neurovascular embolization coil is extra soft and imposes minimal pressure to the aneurysm wall, thus reducing the risk to cause aneurysm rupture or other injury, and is also easier to detach from delivery system with unique mechanical detachment mechanism. Compared to electrolytic detachable coils, this detachment mechanism is instant and there is no need of other special instruments to complete the detachment. also offer more choices of different lengths and diameters for the coils, including six different kinds of 1mm diameter coil.